Why Does the Bottom of Your ELISA Standard Curve Go Flat?
When your lowest standards collapse onto the blank, the assay may not have failed. You may simply be seeing its detection floor — and that floor is determined much more by background and blank variability than by the height of your top standard.
A Flat Lower Curve Is Often a Detection-Limit Problem
Many ELISA runs look perfectly clean at the upper end of the standard curve. Pipetting is consistent, washing is controlled, and the upper standards fit beautifully.
Then the lowest three standards begin to overlap with the blank. The curve stops descending, and low-concentration samples are reported as below range.
This does not automatically mean the run failed. In many cases, the assay has reached the point where low analyte signal can no longer be reliably distinguished from background.
Detection Limits Are Driven by the Blank, Not the Top Standard
Limit of Blank (LoB)
The range of signal expected when no analyte is present.
Limit of Detection (LoD)
The lowest analyte concentration that can be statistically distinguished from the blank.
Lower Limit of Quantitation (LLOQ)
The lowest concentration that can be quantified with acceptable accuracy and precision.
All three metrics are strongly influenced by blank signal and background variability. Increasing assay signal alone therefore does not necessarily improve analytical sensitivity.
What Quietly Raises ELISA Background?
Does More Signal Automatically Mean Better Sensitivity?
Not necessarily.
| Condition | Blank | Low Standard |
|---|---|---|
| Original Assay | 0.10 OD | 0.13 OD |
| 5× Global Signal Increase | 0.50 OD | 0.65 OD |
The absolute signal is much larger, but background increased as well. What matters is improving the separation between true analyte signal and the blank.
This is why selective amplification — increasing analyte-associated signal while maintaining low background — can be far more useful than simply making the plate brighter.
BOLD Amplification for Ultra-Sensitive ELISA
Exazym's BOLD technology is designed to introduce signal amplification into conventional immunoassay workflows while maintaining the low-background performance required for ultra-sensitive protein detection.
Case Study: Plasma Amyloid-Beta
A master's thesis from Uppsala University evaluated a BOLD-amplified ELISA for plasma amyloid-beta.
Background
Signal Increase
Initial LLOQ
Importantly, the thesis also notes that precision and matrix performance require further optimization. The study is therefore best viewed as a development example rather than a diagnostic performance claim.
Case Study: IL-4 in Human Plasma
Low-abundance cytokines such as IL-4 highlight the difference between sensitivity in buffer and true analytical performance in a biological matrix.
A BOLD-amplified IL-4 workflow evaluated detection limit, dilution linearity, spike recovery, and matrix performance in human plasma.
Case Study: Anti-TNF-α ELISA
In an anti-TNF-α ELISA application, BOLD amplification reduced the mean detection limit from 1.38 pg/mL to 0.24 pg/mL.
1.38 → 0.24 pg/mL
Approximately 6-fold improvement
Case Study: Cardiac Troponin I
Cardiac troponin I is a clear example of a biomarker for which the analytical detection floor determines what concentrations can be measured at all.
| Condition | Standard LOD | BOLD LOD | Improvement |
|---|---|---|---|
| Serum / Room Temperature | 12.5 pg/mL | 0.07 pg/mL | Up to 180× |
| Automated / 37°C | 22.7 pg/mL | 0.46 pg/mL | Up to 50× |
A Practical Order of Operations
↓
2. Optimize washing, blocking and antibody concentrations
↓
3. Investigate non-specific binding and matrix effects
↓
4. Evaluate precision at the low end of the curve
↓
5. Establish LoB, LoD and LLOQ
↓
6. Add selective amplification when additional sensitivity is required
Quiet the background first. Amplify the signal second.
Need More Sensitivity From Your ELISA?
If your lowest standards overlap the blank, your biomarker concentrations fall below the usable range of a conventional ELISA, or your plasma or serum matrix is limiting sensitivity, ultra-sensitive amplification may be worth evaluating.
Dana Bioscience can help identify solutions for ELISA development, antibody pairs, cytokine detection and ultra-sensitive biomarker measurement.
Discuss Your Assay
Dana Bioscience
Research Products & Technical Sourcing